Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency

J Infect Dis. 2022 Mar 2;225(5):820-824. doi: 10.1093/infdis/jiab554.

Abstract

Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.

Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.

Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.

Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.

Keywords: COVID-19; SARS-CoV-2; common variable immunodeficiency; monoclonal antibodies; primary antibody deficiencies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use*
  • Antineoplastic Agents, Immunological
  • COVID-19 Drug Treatment*
  • Common Variable Immunodeficiency*
  • Humans
  • Primary Immunodeficiency Diseases / drug therapy*
  • Prospective Studies
  • Real-Time Polymerase Chain Reaction
  • SARS-CoV-2 / isolation & purification*
  • Standard of Care

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Antineoplastic Agents, Immunological

Grants and funding